The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV-Infected Persons.
Mehta, Shruti H. *; Moore, Richard D. +; Thomas, David L. *+; Chaisson, Richard E. +; Sulkowski, Mark S. +
[Article] JAIDS Journal of Acquired Immune Deficiency Syndromes. 33(5):577-584, August 15, 2003.

(Format: HTML, PDF)

Objective: To examine the prevalence and incidence of hyperglycemia among HIV-infected patients by hepatitis C virus (HCV) infection and type of highly active antiretroviral therapy (HAART).

Design: Retrospective cohort analysis of 1230 persons on their first HAART regimen who had at least 1 random glucose measurement before and during antiretroviral therapy.

Methods: The prevalence of hyperglycemia and the incidence of hyperglycemia were compared among persons with and without HCV infection while on a protease inhibitor (PI)-containing HAART regimen, a nonnucleoside reverse transcriptase inhibitor (NNRTI)-containing regimen, or a regimen that contained both a PI and an NNRTI. Hyperglycemia was defined as either 2 random glucose levels > 11.1 mM (200 mg/dL) or documentation of the diagnosis of diabetes in the medical record.

Results: The prevalence of hyperglycemia was significantly higher in HCVcoinfected (5.9%) than HCV-uninfected persons (3.3%, P = 0.02). Among persons receiving HAART, both HCV coinfection (adjusted relative hazard [ARH], 2.28; 95% CI, 1.23-4.22) and PI use (ARH, 5.02; 95% CI, 1.39-18.16) were independent risk factors of developing hyperglycemia. The incidence of hyperglycemia was highest among HCV-coinfected persons receiving a PI (5.6 cases per 100-person years) and only 1 person who was neither HCV-infected nor receiving a PI developed hyperglycemia.

Conclusion: In this urban HIV cohort, the risk of hyperglycemia was increased in HCV-coinfected patients and those prescribed a PI.

(C) 2003 Lippincott Williams & Wilkins, Inc.